TNF Pharmaceuticals Inc. (Nasdaq: TNFA) has announced a new philanthropic collaboration with the DADA2 Foundation to initiate a Compassionate Use (Expanded Access) study of their lead candidate, isomyosamine. This study will evaluate isomyosamine as a potential treatment for the rare pediatric autoinflammatory disease, DADA2 (Deficiency of Adenosine Deaminase 2). Isomyosamine is a novel small molecule TNF-alpha inhibitor that offers an orally administered alternative to standard-of-care biological treatments for DADA2, with the advantage of minimal or no immunosuppression. The study aims to assess its effectiveness in addressing the hyperinflammatory and vasculitic aspects of DADA2, a condition primarily affecting children. The results of this study have not yet been presented.